tiprankstipranks
pc:exciv

Exciva

Exciva is a clinical-stage biopharmaceutical company focused on developing novel therapies for behavioral symptoms associated with Alzheimer's disease (AD). The company is advancing Deraphan, a combination therapy comprising two clinically validated compounds including a new chemical entity, aiming to provide a differentiated safety and efficacy profile for agitation in AD patients.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$51M
Total Amount Raised$51M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$51M
Latest Funding Amount$51M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Jan 20, 2026
Series B
$51.00M

Investors

Investor Name
Funding Round

Related News and Analysis